Company Description
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States.
The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.
It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer.
In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses.
It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2015 |
| IPO Date | Jul 17, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 72 |
| CEO | Jason Lettmann |
Contact Details
Address: 323 Allerton Avenue South San Francisco, California 94080 United States | |
| Phone | 650 466 7125 |
| Website | alxoncology.com |
Stock Details
| Ticker Symbol | ALXO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001810182 |
| CUSIP Number | 00166B105 |
| ISIN Number | US00166B1052 |
| Employer ID | 85-0642577 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jason W. Lettmann | Chief Executive Officer and Director |
| Dr. Jaume Pons Ph.D. | Founder, President, Chief Scientific Officer and Director |
| Dr. Michael Chang Ph.D. | Vice President of Operations |
| Caitlyn Doherty | Manager of Investor Relations and Corporate Communications |
| Dr. Christopher Byrd J.D., Ph.D. | General Counsel |
| Dr. Athanasios Tsiatis M.D. | Senior Vice President of Clinical Development |
| Dr. Lin Yeong-Liang M.D., M.S. | Senior Vice President of Drug Safety and Pharmacovigilance |
| Lisa Sauer | Senior Vice President of Regulatory Affairs and Quality Assurance |
| Sue Naim | Senior Vice President of Clinical Operations |
| Dr. Allison Dillon Ph.D. | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 2, 2024 | SC TO-I | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | 8-K | Current Report |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Oct 10, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 4, 2024 | 8-K | Current Report |